Cryoport Q3 2026 earnings

CYRX · 2026-11-05 16:31 AMC ET · 8-K on SEC

Revenue momentum continued into Q3 with growth across core segments and positive adjusted EBITDA of $1.1 million.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$50.2 million+18%+2.4%Ex. 99.1, Financial Highlights

Revenue breakdown

SegmentActualYoYShare of revenueNote
Life Sciences Services$36.5 million+18%73%BioStorage/BioServices grew 25% YoY
Life Sciences Products$13.7 million+8%27%MVE Biological Solutions drove growth

Margins and costs

  • Gross margin 36.6% (prior 36.4%, change +0.2 pp)
  • Operating expenses $15.3 million (+10% YoY)
  • One-offs in the quarter not stated in the 8-K
  • Effective tax rate 23.3% (prior-year 23.3%, year-to-date 23.3%)
  • Non-GAAP bridge Adds back net interest expense, income taxes, depreciation and amortization, stock-based compensation, acquisition and integration costs, cost reduction initiatives, investment income, unrealized (gain)/loss on investments, foreign currency loss, changes in fair value of contingent consideration, and charges or gains resulting from non-recurring events

KPIs

MetricActualPrior quarterPrior yearChange
Commercial CGT Revenue$7.2 million$6.6 million$6.0 million+20% YoY
BioStorage/BioServices Revenue$12.9 million$10.3 million$10.3 million+25% YoY
BioLogistics Solutions Revenue$23.6 million$20.9 million$20.3 million+16% YoY
Clinical Trials Supported788779737+43 YoY
Commercial Therapies Supported232219+4 YoY

Guidance

MetricGuidePrior guideChange
Full-Year 2026 Revenue$197 million to $199 million$194 million to $196 million+$3 million to $3 million

What drove it

  • Revenue story Life Sciences Services grew 18% YoY, driven by 25% growth in BioStorage/BioServices and 16% growth in BioLogistics Solutions; Life Sciences Products grew 8% YoY.
  • EPS story Adjusted EBITDA turned positive to $1.1 million, representing a $1.1 million increase from the prior year.
  • One-off check None disclosed in the release.

The good

  • Positive adjusted EBITDA of $1.1 million
  • Revenue growth across all core segments
  • Record clinical trial count of 788

The bad

  • Operating expenses increased 10% YoY

The ugly

  • none

Open questions

  • The reconciliation tables for GAAP to adjusted EBITDA are truncated in the release text.
  • Specifics on the prior-year adjusted EBITDA figure are not provided in the text.
Full release

Cryoport (CYRX) earnings release, November 5, 2026

Cryoport, Inc. (CYRX) · Form 8-K, Item 2.02 · Filed · SEC filing

Cryoport

Reports Third Quarter 2026 Financial Results

NASHVILLE,

Tennessee, November 5, 2026, -

Cryoport, Inc.

(NASDAQ: CYRX) (“Cryoport” or the “Company”), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2026.

Jerrell

Shelton, CEO of Cryoport, stated, “Cryoport delivered third quarter revenue of $50.2 million, reflecting continued momentum across our core cell and gene therapy (CGT) business. Revenue from commercial CGT clients increased 20% year over year, BioStorage/BioServices revenue expanded 25%, and total Life Sciences Services revenue grew 18%, underscoring the strength of our integrated platform and the growing demand for our solutions. These results reflect both the increasing number of patients worldwide receiving CGT treatments and the continued adoption of our end-to-end temperature-controlled supply chain solutions. We also achieved 8% year over year growth in

Life Sciences Products revenue, supported by MVE Biological Solutions’ (MVE) position as the global market leader in cryogenic systems.”

“During the quarter, we further strengthened our leadership position within the CGT ecosystem, ending the period supporting 23 commercial therapies and a record of 788 clinical trials worldwide. Our integrated platform, disciplined execution, and growing utilization of our Global

Supply Chain Center Network continue to enhance scalability and operating leverage, advancing our progress toward sustained profitability.

This momentum was reflected in our positive adjusted EBITDA of $1.1 million for the quarter, representing another important milestone in our pathway to profitability initiative.

“Our strong year-to-date performance, combined with expanding support of commercial therapies, deepening customer relationships, a robust clinical trial pipeline, and continued demand for MVE’s industry-leading products, gives us confidence in our outlook. As a result, we are increasing our full-year 2026 revenue guidance to a range of $197 million to $199 million,” concluded Mr. Shelton.¹

The following table presents Q3 2026 revenue compared with Q3 2025:

Cryoport, Inc. and Subsidiaries

Revenue

BioLogistics

Solutions revenue increased 16% year-over-year in Q3 2026, driven by continued commercial therapies development, and clinical trial progress within the CGT market. BioStorage/BioServices revenue grew 25% year-over-year, reflecting another strong quarter of demand for our expanded, integrated services offering, which provides seamless, secure handling of temperature-sensitive materials across our global network.

As of September 30, 2026, the number of commercial cell and gene therapies we support increased to 23 and our total global clinical trial count that we support rose to 788 clinical trials, a net increase of 43 clinical trials over September 30, 2025, with 99 of these clinical trials in Phase 3. The number of trials by phase and region are as follows:

Cryoport

Supported Clinical Trials by Phase

Cryoport

Supported Clinical Trials by Region

In

Q3 2026, Cryoport’s customer, Replimune, received accelerated U.S. Food and Drug Administration (FDA) approval for TUDRIQEV™ for the treatment of adults with unresectable advanced cutaneous melanoma, a skin cancer that has spread too widely or deeply to be safely or completely removed with surgery. Also, during the quarter Crispr Therapeutics and their partner Vertex Pharmaceuticals received FDA supplemental approval to expand the label of CASGEVY® for treatment of people 2 years of age and older with either Sickle

Cell Disease (SCD) or Transfusion-dependent Beta Thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT .²

Two of Cryoport’s customers filed Biologics License Applications (BLA) with the FDA in the third quarter and we anticipate another five possible BLA or

Marketing Authorization

Applications (MAA) in 2026. Cryoport also anticipates two possible additional new therapy approvals (both of which have received Prescription

Drug User Fee Act (PDUFA) dates from the FDA for Q4 2026), and one possible additional supplemental approval for geographic expansion from our customer base this year.

Operational

Milestones

Financial

Highlights

On

June 11, 2025, the Company completed the divestiture of its CRYOPDP specialty courier business to DHL Group. The results of CRYOPDP, a former business within Cryoport’s Life Sciences Services segment, are presented as discontinued operations for all periods and are excluded from the non-GAAP financial measures in this release.

Revenue³

Gross

Margin

Operating

Costs and Expenses

Loss from Continuing Operations

Net

Income (Loss) – including Discontinued Operations

Adjusted

EBITDA from Continuing Operations

Cash,

Cash equivalents, and Short-Term Investments⁴

Revenue

Guidance for Full-Year 2026

Note:

All reconciliations of GAAP to adjusted (non-GAAP) figures above are detailed in the reconciliation tables included later in the press release.

Additional

Information

Further information on Cryoport’s financial results is included in the attached condensed consolidated balance sheets and statements of operations, and additional explanations of Cryoport’s financial performance are provided in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which is expected to be filed with the Securities and Exchange Commission ("SEC") on November 5, 2026. Additionally, the full report will be available in the SEC Filings section of the Investor Relations section of... (truncated) www.cryoportinc.com.

Earnings

Conference Call Information

IMPORTANT

INFORMATION

: In addition to the earnings release, a document titled “Cryoport Third Quarter 2026 in Review,” providing a review of Cryoport’s business update, will be issued at 4:05 p.m. ET on Thursday, November 5, 2026. The document is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.

Cryoport management will host a conference call at 5:00 p.m. ET on November 5, 2026. The conference call will be in the format of a questions and answers session and will address any queries investors have regarding the Company’s reported results. A slide deck will accompany the call.

Conference

Call Information⁵

The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor

Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until November 12, 2026. To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1107312#.

About

Cryoport, Inc.

Cryoport,

Inc.

(Nasdaq: CYRX) is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal®

Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized BioLogistics, BioStorage, BioServices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are

"Enabling the Future of Medicine™."

Headquartered in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.

For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at https://x.com/cryoport for live updates.⁶

Forward-Looking

Statements

Financial statements

Balance Sheet

September 30, — Condensed Consolidated Balance Sheets (in thousands)

September 30, – 2026 – (unaudited)December 31, – 2025
Current assets
Cash and cash equivalents279,179250,494
Short-term investments113,897160,714
Accounts receivable, net36,00433,359
Inventories22,43823,188
Prepaid expenses and other current assets5,1868,419
Total current assets456,704476,174
Property and equipment, net96,36785,448
Operating lease right-of-use assets39,47339,720
Intangible assets, net133,277138,082
Goodwill22,03022,400
Deposits1,9982,092
Deferred tax assets1,0961,073
Total assets750,945764,989
Current liabilities
Accounts payable and other accrued expenses16,34715,283
Accrued compensation and related expenses14,73112,980
Deferred revenue1,455943
Current portion of operating lease liabilities4,3784,133
Current portion of finance lease liabilities448422
Current portion of convertible senior notes, net185,986185,094
Current portion of notes payable159163
Current portion of contingent consideration674
Total current liabilities224,178219,018
Notes payable, net9471,087
Operating lease liabilities, net38,90539,078
Finance lease liabilities, net688741
Deferred tax liabilities1,7481,354
Other long-term liabilities965444
Contingent consideration629
Total liabilities267,431262,351
Total stockholders' equity483,514502,638
Total liabilities and stockholders' equity750,945764,989

Statements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities

Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as the

Company's outlook and guidance for full-year 2026 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Company operates, the Company's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, the Company’s expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of the Company's clients. Forward-looking statements also include those related to the Company’s plans regarding its Global Supply Chain Centers, including expected timing of future openings, the Company’s anticipation that it will benefit from its operating leverage, the Company’s belief that it is well positioned to further expand margins, enhance operating efficiency and deliver sustainable, profitable long-term growth for its shareholders, and the Company’s expectation that upcoming growth catalysts in its business segments will drive the Company to new heights in market position, growth, and productivity. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effects of changing economic and geopolitical conditions, such as those resulting from the war with Iran, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in the Company’s cash flow, market acceptance risks, the effects of tariffs and other trade restrictions, and technical development risks. The Company's business could be affected by other factors discussed in the Company's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation and does not undertake to update or revise any forward-looking statements in this press release.

Cryoport

Investor Contacts:

Todd

Fromer / Scott Eckstein

KCSA

Strategic Communications cryoport@kcsa.com⁷

Cryoport, Inc. and Subsidiaries... (truncated)ents of Operations⁸

Cryoport, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets⁹

Note Regarding Use of Non-GAAP

Financial Measures

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measure of financial performance as defined in Regulation G of the Securities Exchange Act of 1934 is included in this release: adjusted

EBITDA from continuing operations. Non-GAAP financial measures are not calculated in accordance with GAAP, are not based on any comprehensive set of accounting rules or principles and may be different from non-GAAP financial measures presented by other companies. Non-GAAP financial measures, including adjusted EBITDA from continuing operations, should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

Adjusted

EBITDA from continuing operations is defined as loss from continuing operations adjusted for net interest expense, income taxes, depreciation and amortization expense, stock-based compensation expense, acquisition and integration costs, cost reduction initiatives, investment income, unrealized (gain)/loss on investments, foreign currency loss, changes in fair value of contingent consideration and charges or gains resulting from non-recurring events, as applicable.

Management believes that adjusted EBITDA from continuing operations provides a useful measure of Cryoport's operating results, a meaningful comparison with historical results and with the results of other companies, and insight into Cryoport's ongoing operating performance. Further, management and the Company’s board of directors utilize adjusted EBITDA from continuing operations to gain a better understanding of Cryoport's comparative operating performance from period to period and as a basis for planning and forecasting future periods. Adjusted

EBITDA from continuing operations is also a significant performance measure used by Cryoport in connection with its incentive compensation programs. Management believes adjusted EBITDA from continuing operations, when read in conjunction with Cryoport's GAAP financials, is useful to investors because it provides a basis for meaningful period-to-period comparisons of Cryoport's ongoing operating results, including results of operations, against investor and analyst financial models, helps identify trends in Cryoport's underlying business and in performing related trend analyses, and it provides a better understanding of how management plans and measures Cryoport's underlying business.¹⁰

Cryoport, Inc. and Subsidiaries

Reconciliation of GAAP loss from continuing operations to adjusted EBITDA

(unaudited)¹¹

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.